Methods of using 18903 to treat pain and pain-related disorders
AssigneeMillennium Pharmaceuticals, Inc.
InventorsRosana Kapeller-Libermann, Inmaculada Silos-Santiago
Life of this patent
Estimating the term…
Abstract
The invention provides isolated nucleic acid molecules, designated COE-2 nucleic acid molecules, which encode novel carboxylesterase family members. The invention also provides antisense nucleic acid molecules, recombinant expression vectors containing COE-2 nucleic acid molecules, host cells into which the expression vectors have been introduced, and nonhuman transgenic animals in which a COE-2 gene has been introduced or disrupted. The invention still further provides isolated COE-2 proteins, fusion proteins, antigenic peptides and anti-COE-2 antibodies. Diagnostic and therapeutic methods utilizing compositions of the invention are also provided.
Claims32
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:
- 1, or a complement thereof;
- and
- (b) a nucleic acid molecule comprising the nucleotide sequence set forth in SEQ ID NO:
- 3, or a complement thereof.
An isolated nucleic acid molecule which encodes a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2, or a complement thereof.
An isolated nucleic acid molecule comprising the nucleotide sequence contained in the plasmid deposited with ATCC® as Accession Number ______.
An isolated nucleic acid molecule which encodes a naturally-occurring allelic variant of a polypeptide comprising the amino acid sequence set forth in SEQ ID NO:
- 2, or a complement thereof.
An isolated nucleic acid molecule selected from the group consisting of:
- (a) a nucleic acid molecule comprising a nucleotide sequence which is at least 93% identical to the nucleotide sequence of SEQ ID NO:
- 1 or 3, or a complement thereof;
- (b) a nucleic acid molecule comprising at least 828 nucleotides of the nucleotide sequence of SEQ ID NO:
- 1 or 3, or a complement thereof;
- (c) a nucleic acid molecule which encodes a polypeptide comprising an amino acid sequence at least about 63% identical to the amino acid sequence of SEQ ID NO:
- 2;
- and
- (d) a nucleic acid molecule which encodes a fragment of a polypeptide comprising at least 273 contiguous amino acid residues of the amino acid sequence of SEQ ID NO:
- 2.
An isolated polypeptide selected from the group consisting of:
- a) a fragment of a polypeptide comprising at least 273 contiguous amino acids of SEQ ID NO:
- 2;
- b) a naturally occurring allelic variant of a polypeptide comprising the amino acid sequence of SEQ ID NO:
- 2, wherein the polypeptide is encoded by a nucleic acid molecule which hybridizes to the complement of a nucleic acid molecule consisting of SEQ ID NO:
- 1 or 3 under stringent conditions;
- c) a polypeptide which is encoded by a nucleic acid molecule comprising a nucleotide sequence which is at least 93 % identical to a nucleic acid comprising the nucleotide sequence of SEQ ID NO:
- 1 or 3;
- and
- d) a polypeptide comprising an amino acid sequence which is at least 63% identical to the amino acid sequence of SEQ ID NO:
- 2.
A method for detecting the presence of a COE-2 nucleic acid molecule in a sample comprising:
- a) contacting the sample with a nucleic acid probe or primer which selectively hybridizes to the nucleic acid molecule;
- and
- b) determining whether the nucleic acid probe or primer binds to a nucleic acid molecule in the sample to thereby detect the presence of a COE-2 nucleic acid molecule in the sample.
A method of identifying a nucleic acid molecule associated with an inflammatory or pain disorder comprising:
- a) contacting a sample comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:
- 1;
- and
- b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a nucleic acid molecule associated with an inflammatory or pain disorder.
A method of identifying a nucleic acid associated with an inflammatory or pain disorder comprising:
- a) contacting a sample comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:
- 1 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:
- 1;
- b) incubating said sample under conditions that allow nucleic acid amplification;
- and
- c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a nucleic acid molecule associated with an inflammatory or pain disorder.
A method of identifying a polypeptide associated with an inflammatory or pain disorder comprising:
- a) contacting a sample comprising polypeptides with a binding substance which specifically binds to COE-2;
- and
- b) detecting the presence of a polypeptide in said sample that binds to said COE-2 binding substance, thereby identifying a polypeptide associated with an inflammatory or pain disorder.
A method of identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a hybridization probe comprising at least 25 contiguous nucleotides of SEQ ID NO:
- 1;
- and
- b) detecting the presence of a nucleic acid molecule in said sample that hybridizes to said probe, thereby identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder.
A method of identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder comprising:
- a) contacting a sample obtained from said subject comprising nucleic acid molecules with a first and a second amplification primer, said first primer comprising at least 25 contiguous nucleotides of SEQ ID NO:
- 1 and said second primer comprising at least 25 contiguous nucleotides from the complement of SEQ ID NO:
- 1;
- b) incubating said sample under conditions that allow nucleic acid amplification;
- and
- c) detecting the presence of a nucleic acid molecule in said sample that is amplified, thereby identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder.
A method of identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder comprising:
- a) contacting a sample obtained from said subject comprising polypeptides with a COE-2 binding substance;
- and
- b) detecting the presence of a polypeptide in said sample that binds to said COE-2 binding substance, thereby identifying a subject having an inflammatory or pain disorder, or at risk for developing an inflammatory or pain disorder.
A method for identifying a compound capable of treating an inflammatory or pain disorder characterized by aberrant COE-2 nucleic acid expression or COE-2 polypeptide activity comprising assaying the ability of the compound to modulate COE-2 nucleic acid expression or COE-2 polypeptide activity, thereby identifying a compound capable of treating an inflammatory or pain disorder characterized by aberrant COE-2 nucleic acid expression or COE-2 polypeptide activity.
A method for treating a subject having an inflammatory or pain disorder characterized by aberrant COE-2 polypeptide activity or aberrant COE-2 nucleic acid expression comprising administering to the subject a COE-2 modulator, thereby treating said subject having an inflammatory or pain disorder.
Dependencies are inferred from the claim text.